The Dry Powder Inhaler Market is poised for significant growth, with a market value of USD 20.83 billion in 2024, projected to climb to USD 29.95 billion by 2034, representing a steady CAGR of 3.70% ...

Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "Dry Powder Inhaler Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. The dry powder inhaler market size has grown strongly ...

Switching from a metered-dose to a dry-powder inhaler after a formulary change increased emergency department visits and hospitalizations in people with COPD or asthma. The absolute changes in risk ...

Please provide your email address to receive an email when new articles are posted on . A metered-dose inhaler was switched to a dry-powder inhaler in Veterans Affairs facilities. Veterans who did vs.

Dry Powder Inhalers: A Double Win for COPD and Environment By Dennis Thompson HealthDay ReporterTUESDAY, Feb. 24, 2026 (HealthDay News) — Dry powder inhalers might provide a double benefit for people ...

Dry powder inhalers (DPIs) have become a mainstay in the management of chronic pulmonary diseases such as chronic obstructive pulmonary disease and asthma. Their performance depends on a complex ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

Please provide your email address to receive an email when new articles are posted on . A metered-dose inhaler was switched to a dry-powder inhaler in July 2021 in Veterans Affairs facilities. The ...

Switching from a metered dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler. The Food and Drug Administration (FDA) has approved ...